Tratamiento por objetivos en el lupus eritematoso sistémico

Roberto Ríos-Garcés; Gerard Espinosa; Ronald van Vollenhoven; Ricard Cervera

doi:https://doi.org/10.1016/j.rcreu.2021.05.002

Tratamiento por objetivos en el lupus eritematoso sistémico

Translated title of the contribution: Treat to target in systemic lupus erythematosus

Roberto Ríos-Garcés, Gerard Espinosa, Ronald van Vollenhoven, Ricard Cervera

Research output: Contribution to journal › Review article › Professional

1 Citation (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is the most representative disorder within systemic autoimmune diseases. The treat-to-target strategy in SLE was established half a decade ago and, since then, remarkable advances have been made. An international consensus has defined and unified the term remission and also low disease activity has been proposed as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials.

Translated title of the contribution	Treat to target in systemic lupus erythematosus
Original language	Spanish
Pages (from-to)	101-106
Number of pages	6
Journal	Revista Colombiana de Reumatologia
Volume	28
Early online date	2021
DOIs	https://doi.org/10.1016/j.rcreu.2021.05.002
Publication status	Published - Jun 2021

Keywords

Lupus low disease activity
Remission
Systemic lupus erythematosus
Treat-to-target

Access to Document

https://doi.org/10.1016/j.rcreu.2021.05.002

Cite this

@article{ea544d5a3cb34a7d8601a65577f1a363,

title = "Tratamiento por objetivos en el lupus eritematoso sist{\'e}mico",

abstract = "Systemic lupus erythematosus (SLE) is the most representative disorder within systemic autoimmune diseases. The treat-to-target strategy in SLE was established half a decade ago and, since then, remarkable advances have been made. An international consensus has defined and unified the term remission and also low disease activity has been proposed as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials.",

keywords = "Lupus low disease activity, Remission, Systemic lupus erythematosus, Treat-to-target",

author = "Roberto R{\'i}os-Garc{\'e}s and Gerard Espinosa and {van Vollenhoven}, Ronald and Ricard Cervera",

note = "Publisher Copyright: {\textcopyright} 2021 Asociaci{\'o}n Colombiana de Reumatolog{\'i}a",

year = "2021",

month = jun,

doi = "https://doi.org/10.1016/j.rcreu.2021.05.002",

language = "Spanish",

volume = "28",

pages = "101--106",

journal = "Revista Colombiana de Reumatologia",

issn = "0121-8123",

publisher = "Asociacion Colombiana de Reumatologia",

}

TY - JOUR

T1 - Tratamiento por objetivos en el lupus eritematoso sistémico

AU - Ríos-Garcés, Roberto

AU - Espinosa, Gerard

AU - van Vollenhoven, Ronald

AU - Cervera, Ricard

PY - 2021/6

Y1 - 2021/6

N2 - Systemic lupus erythematosus (SLE) is the most representative disorder within systemic autoimmune diseases. The treat-to-target strategy in SLE was established half a decade ago and, since then, remarkable advances have been made. An international consensus has defined and unified the term remission and also low disease activity has been proposed as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials.

AB - Systemic lupus erythematosus (SLE) is the most representative disorder within systemic autoimmune diseases. The treat-to-target strategy in SLE was established half a decade ago and, since then, remarkable advances have been made. An international consensus has defined and unified the term remission and also low disease activity has been proposed as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials.

KW - Lupus low disease activity

KW - Remission

KW - Systemic lupus erythematosus

KW - Treat-to-target

UR - http://www.scopus.com/inward/record.url?scp=85107078371&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.rcreu.2021.05.002

DO - https://doi.org/10.1016/j.rcreu.2021.05.002

M3 - Review article

SN - 0121-8123

VL - 28

SP - 101

EP - 106

JO - Revista Colombiana de Reumatologia

JF - Revista Colombiana de Reumatologia

ER -

Tratamiento por objetivos en el lupus eritematoso sistémico

Abstract

Keywords

Access to Document

Other files and links

Cite this